CSL (CSLLY) AI Stock Analysis

60 Followers

CSL

(Other OTC:CSLLY)

Select Model

Rating:64Neutral

Price Target:$37.00▲(7.61% Upside)

Action:reiterated

Date:08/19/26

The overall score of 64 balances exceptional cash generation and strong market momentum against major statutory losses and valuation concerns. The primary risks stem from a massive $7.1 billion impairment and structural headwinds in the Vifor portfolio, which drove the recent GAAP net loss. However, the company's core operations remain highly resilient, evidenced by $3.52 billion in operating cash flow, extensive share buybacks, and stabilizing demand in key segments like CSL Behring. While technical indicators confirm a robust uptrend, extreme overbought signals and an elevated P/E ratio of 36.01x warrant near-term caution.

Positive Factors

Resilient cash generationConsistently positive operating and free cash flow gives CSL internal funding for research, capacity, debt service, dividends, and buybacks. This cash engine supports strategic flexibility and provides a durable foundation even when reported earnings are affected by noncash charges.

Negative Factors

Structural Vifor declineVifor faces several durable portfolio pressures rather than a single temporary setback, including generic competition, European price erosion, and the loss of reimbursement support. Its expected FY27 contraction creates a meaningful drag on group growth and resource returns.

CSL (CSLLY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $133.25B
Dividend Yield: 2.08%
Average Volume (3M): 128.60K
Price to Earnings (P/E): -26.0
Beta (1Y): 0.25
Revenue Growth: 2.19%
EPS Growth: -187.48%
Country: US
Employees: 29,000
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CSL Business Overview & Revenue Model

Company Description

CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international...

How the Company Makes Money

CSL makes money primarily by selling high-value specialty biologic medicines and vaccines through three main business segments. (1) CSL Behring generates revenue from plasma-derived and recombinant therapies used to treat conditions such as immunodef...

CSL Earnings Call Summary

Earnings Call Date:Aug 17, 2026(Q4-2026)|% Change Since:45.43%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentNeutral

The call presents a mixed picture: operational and commercial turnaround actions are beginning to show early, tangible benefits (strong cash flow, successful transformation savings, Seqirus market outperformance, Ig momentum and promising product launches), but these positives are offset by very large impairments, significant and structural headwinds in Vifor (expected ~25% revenue decline in FY'27), continued albumin pricing pressure in China and an FY'26 statutory loss driven by noncash charges. Management’s FY'27 underlying guidance (NPAT +~5% cc; Behring growth) and capital returns indicate confidence in a return to profitable growth, yet the scale of recent impairments and the outlook for Vifor mean near-term headwinds remain material.

Positive Updates

Strong cash generation and capital returns

Operating cash flow of $3.5 billion supported completion of an AUD 1.0 billion share buyback, a new AUD 1.1 billion buyback authorization for FY'27, and maintenance of the full-year dividend at $2.92 per share (U.S. dollar basis); net debt/EBITDA finished at 1.8x within target range.

Negative Updates

Very large impairments and statutory loss

Total pretax impairments of $7.1 billion for FY'26 (including $5.5 billion in H2), with a $4.1 billion impairment primarily related to Vifor. After restructuring and impairments, statutory NPAT attributable to CSL shareholders was a loss of $2.6 billion.

Company Guidance

CSL guided FY '27 group revenue to be broadly in line with FY '26 (FY '26 revenue $15.8bn, -1% cc) and expects underlying NPAT (excluding restructuring and impairments) to grow by approximately 5% at constant currency (noting an estimated FX headwind of about $50m at current rates). By business, CSL Behring is expected to deliver mid‑single‑digit revenue growth with immunoglobulin growing mid‑ to high‑single digits and a modest gross‑margin improvement, Seqirus low‑single‑digit revenue growth, and CSL Vifor a ~25% revenue decline (no TAVNEOS sales included in guidance). The transformation program should deliver ~ $220m incremental savings in FY '27 (building on $176m delivered in FY '26) taking annualized savings to ~ $400m and up to $550m in FY '28, with roughly half the incremental savings to be reinvested; FY '27 CapEx is expected to be about $1.0bn ± $100m. Capital return and balance‑sheet items include a new share buyback of ~AUD 1.1bn, the dividend maintained in US$ (FY '26 full‑year $2.92 per share, final $1.62), and a target net‑debt/EBITDA range of 1.5–2x.

CSL Financial Statement Overview

Summary

Exceptional operating cash flow ($3.52B) and a manageable debt-to-equity ratio (0.73) anchor the financials, providing strong liquidity. However, this is significantly offset by a severe transition from robust profitability to a $2.59B net loss, which has eroded the equity base.

Income Statement

50Neutral

Balance Sheet

65Positive

Cash Flow

88Very Positive

Financial statement breakdown
Breakdown	TTM	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022
Income Statement
Total Revenue	15.74B	15.77B	15.43B	14.80B	13.17B	10.49B
Gross Profit	7.51B	7.52B	7.95B	7.56B	6.71B	5.66B
EBITDA	5.05B	5.07B	5.13B	4.74B	3.90B	3.46B
Net Income	-2.59B	-2.59B	3.00B	2.64B	2.19B	2.25B
Balance Sheet
Total Assets	33.65B	33.65B	39.40B	38.02B	36.23B	28.35B
Cash, Cash Equivalents and Short-Term Investments	1.51B	1.51B	2.16B	1.66B	1.55B	10.44B
Total Debt	10.90B	10.90B	11.50B	12.18B	12.23B	9.66B
Total Liabilities	17.34B	17.34B	18.00B	18.62B	18.41B	13.77B
Stockholders Equity	14.80B	14.80B	19.34B	17.36B	15.79B	14.58B
Cash Flow
Free Cash Flow	2.88B	2.88B	2.54B	1.51B	909.00M	1.38B
Operating Cash Flow	3.52B	3.53B	3.56B	2.76B	2.60B	2.63B
Investing Cash Flow	-1.28B	-1.28B	-850.00M	-1.26B	-11.84B	-1.64B
Financing Cash Flow	-2.84B	-2.84B	-2.24B	-1.28B	456.00M	7.68B

CSL Technical Analysis

Technical Analysis SentimentPositive

Last Price34.38

Price Trends

50DMA32.72Positive

100DMA28.24Positive

200DMA25.50Positive

Market Momentum

MACD0.62Positive

RSI56.04Neutral

STOCH20.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Positive. The current price of 34.38 is below the 20-day moving average (MA) of 34.63, above the 50-day MA of 32.72, and above the 200-day MA of 25.50, indicating a neutral trend. The MACD of 0.62 indicates Positive momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 20.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CSLLY.

CSL Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CSLLY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	81Outperform	$98.38B	20.35	15.07%	0.39%	18.59%	8.14%
ARGX	76Outperform	$61.46B	45.54	16.86%	―	70.57%	30.28%
MRNA	71Outperform	$93.61B	-31.59	-37.62%	―	13.13%	12.35%
CSLLY	64Neutral	$66.46B	-25.98	-15.12%	2.08%	2.19%	-187.48%
BMRN	56Neutral	$10.98B	-635.89	-0.31%	―	19.76%	-103.57%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNTX	49Neutral	$21.08B	-12.93	-8.09%	―	-20.72%	-160.57%

* Healthcare Sector Average

Performance Comparison

CSLLY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CSLLY	Csl Ltd	34.38	5.71	19.90%
BMRN	Biomarin Pharmaceutical Inc.	57.23	2.77	5.09%
REGN	Regeneron Pharmaceuticals	955.47	254.75	36.36%
ARGX	Argenx	960.04	30.43	3.27%
MRNA	Moderna	223.37	198.61	802.14%
BNTX	Biontech Se Sponsored Adr	85.60	-17.07	-16.63%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 19, 2026

CSL AI Stock Analysis